Abstract 577P
Background
Treatment options for refractory MSS/MSI-L CRC are limited, with no FDA-approved ICI therapies. Such tumors have high collagen deposition in the extracellular matrix (ECM) resulting in a barrier to immune cell infiltration and ICI resistance. NC410 is a dimeric Leukocyte Associated Immunoglobulin-Like Receptor-2 (LAIR-2) protein fused to a human IgG1 Fc domain. NC410 targets collagen, promotes ECM remodeling, immune cell infiltration, and reverses immunosuppression mediated by LAIR-1 inhibitory receptor. NC410 and anti-PD-1/PD-L1 combination potentiates anti-tumor activity in preclinical models.
Methods
A Phase 1b study of NC410 plus pembrolizumab in advanced solid tumors was conducted (NCT05572684). MSS/MSI-L CRC patients (n=70) received pembrolizumab (400mg Q6W) on Day 1 and escalating doses of NC410 at 30 (n=3), 60 (n=9), 100 (n=48), and 200mg (n=10) Q2W on Days 1, 15, and 29 of a 42-day cycle following a modified Toxicity Probability Interval (mTPI) design. The data cut-off was 1-May-2024.
Results
The combination therapy is safe and tolerable with Gr≥3 treatment emergent (31%) and related (4%) adverse events (AEs). The study was enriched for CRC without liver metastases (LM-) at 100 and 200mg NC410, evaluated for RP2D. There were 50 evaluable LM- CRC patients at various dose levels, with 2 PRs and 24 SD (DCR: 52%), compared to 13 evaluable LM+ patients with 2 SD (DCR: 15%). At the 200mg dose level, amongst 9 evaluable patients (all LM-), 5 were SD (no reduction in tumor size) and 4 PD per RECIST 1.1. The 100mg dose level was comprised of 44 ICI naïve, of which 41 were LM- with 5 median prior lines of treatment (range 1-10), and 4 ICI refractory patients. Of the ICI refractory group, only 1 had SD. Of the 37 evaluable LM- CRC, 2 had confirmed ongoing PRs (>12+ mo and > 7+ mo), 17 SD, and 18 PD. DCR of the 100mg LM- group was 51.3% (19/37) [CI: 34.4, 68.1], with ORR of 5.4% (2/37) [CI: 0.7, 18.2]. On-treatment biopsy of a PR patient showed an increase in CD8+ effector memory T cells and reduction in myelosuppressive cells in the TME, compared to baseline.
Conclusions
NC410 plus pembrolizumab combo is a well-tolerated treatment option with clinical benefit in hard-to-treat metastatic CRC that merits further evaluation in a randomized study.
Clinical trial identification
NCT05572684.
Editorial acknowledgement
Legal entity responsible for the study
NextCure Inc.
Funding
NextCure Inc.
Disclosure
E.S. Christenson: Financial Interests, Personal, Advisory Board, Consultant for Seres Therapeutics: Seres Therapeutics; Financial Interests, Personal, Advisory Board, Advisory board: SIRTex therapeutics; Financial Interests, Institutional, Coordinating PI, PI on a trial for NextCure: NextCure; Financial Interests, Institutional, Research Grant, Research grant from Pfizer: Pfizer; Financial Interests, Institutional, Coordinating PI, PI for clinical trial with Regeneron: Regeneron; Financial Interests, Institutional, Local PI, PI for clinical trial: Affimed Gmbh. S. Kazmi: Financial Interests, Personal, Stocks/Shares: johnson and johnson. D. Sohal: Financial Interests, Personal, Invited Speaker: InCyte, SeaGen; Financial Interests, Personal, Advisory Board: Totus, Valar, Cancer Commons; Financial Interests, Institutional, Trial Chair: Ability Pharma, AstraZeneca; Financial Interests, Institutional, Local PI: Amgen, Apexigen, Astellas, Bexion, BMS, FibroGen, Genentech, Hengrui, Merck, Mirati, NextCure, PanCAN, Regeneron, Roche. S. Manda: Financial Interests, Personal, Advisory Board, Scientific advisor: Reglagene; Financial Interests, Personal, Stocks/Shares: Reglagene. A. Martz: Financial Interests, Personal, Full or part-time Employment: NextCure, Inc; Financial Interests, Personal, Stocks/Shares: NextCure, Inc. S. Kordahi: Financial Interests, Personal, Full or part-time Employment, Senior Director, Clinical Operations: NextCure, Inc.; Financial Interests, Personal, Stocks/Shares, Stock Options Grant: NextCure, Inc. M. Zika: Financial Interests, Personal, Full or part-time Employment: nextcure; Financial Interests, Personal, Stocks/Shares: nextcure. P. Kothari: Financial Interests, Institutional, Full or part-time Employment: NextCure. S. Kahan: Financial Interests, Personal, Full or part-time Employment, Employeed by Nextcure, Inc,: Nextcure, Inc. E.A. Barbu: Financial Interests, Institutional, Full or part-time Employment: NextCure, Inc.; Financial Interests, Personal, Stocks/Shares: NextCure, Inc.; Non-Financial Interests, Institutional, Proprietary Information: NextCure, Inc. A. Morawski: Financial Interests, Institutional, Full or part-time Employment: NextCure, Inc.; Financial Interests, Institutional, Stocks/Shares, Granted Stock Options: NextCure, Inc. D. Flies: Financial Interests, Personal, Full or part-time Employment: NextCure; Financial Interests, Personal, Stocks/Shares: NextCure. S.A.R. Langermann: Financial Interests, Institutional, Full or part-time Employment, CSO: NextCure, Inc.; Financial Interests, Institutional, Stocks/Shares: NextCure, Inc. M. Chisamore: Financial Interests, Institutional, Full or part-time Employment: Merck & Co. Inc; Financial Interests, Institutional, Stocks/Shares: Merck & Co. Inc. S. Fu: Financial Interests, Institutional, Research Grant, Partial grant funding supporting facilities necessary for clinical trials.: NIH/NCI P30CA016672 – Core Grant (CCSG Shared Resources); Financial Interests, Institutional, Local PI: Abbisko, Antengene, BeiGene, Ltd, BeyondSpring Phamaceuticals, Inc., BioAtla, LLC., Boehringer Ingelheim, CUE Biopharma, Inc., DEKA Biosciences, Eli Lilly & Co., Exelixis, Greenfire Bio, Inc., Hookipa Biotech, ImmavRx, Inc. (IMV), Innovent Biologics, Co., Ltd., Jazz Pharmaceuticals, K-Group Beta, Lantern Pharma Inc., Lyvgen Biopharm, Co., Ltd., MacroGenics, MediLink Therapeutics, Co. Ltd., Millennium Pharmaceuticals, inc., Nerviano Medical Sciences, NeuPharma, Inc., NextCure, Inc., Ningbo NewBay Technology Development Co., Ltd., Novartis, NovoCure, Nykode Therapeutics, Parexel International, LLC, PharmaMar USA, Inc., Pionyr Immunotherapeutics, Inc., PureTech Health, LLC, Qurgen, Inc., Sellas Life Sciences Group, Shanghai Huaota Biopharmaceutical Co., Ltd., Soricimed Biopharma, Inc., SQZ Biotechnologies, Sumitomo Dainippon, Taiho Oncology and NCCN, Treadwell Therapeutics, Turnstone Biologics, Tyligand Bioscience, Ltd., Virogin Biotech, Ltd. R. Wadlow: Financial Interests, Personal, Advisory Board, Advisory Board: Exact Sciences; Financial Interests, Personal, Advisory Board: Pfizer. U. Guha: Financial Interests, Personal, Full or part-time Employment, employee of NextCure Inc.: NextCure Inc.; Financial Interests, Personal, Stocks/Shares, current employee stock options: NextCure Inc.; Financial Interests, Personal, Stocks/Shares, Prior employee of TCR2 Therapeutics- now Adaptimmune: TCR2/Adaptimmune. H. Myint: Financial Interests, Personal, Full or part-time Employment, Chief Medical Officer: NextCure Inc; Financial Interests, Personal, Stocks/Shares: NextCure Inc. D. Le: Financial Interests, Personal, Advisory Board: Merck, BMS, Nouscom, Janssen, Regeneron, G1 Therapeutics, Tavotek, Catenion, Sirtex, Tango Therapeutics, Endeavor Biosciences, Merus; Financial Interests, Personal, Other, Advice: Bayer; Financial Interests, Institutional, Local PI: Merck, BMS, Curegenix, Nouscom, Abbvie, Dynamicure. All other authors have declared no conflicts of interest.
Resources from the same session
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16